Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Investor Alert: Deadline in Lawsuit on April 07, 2026

A deadline is coming up on April 07, 2026 in the lawsuit filed for certain investors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) over alleged securities laws violations by Inovio Pharmaceuticals, Inc.

Investors who purchased shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) have certain options and there are strict and short deadlines running. Deadline: April 07, 2026. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Plymouth Meeting, PA based Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicines are comprised of two components: (i) DNA plasmids, which are small circular DNA molecules that purportedly work like software that the body's cells can download to produce specific proteins to target and fight disease; and (ii) its proprietary investigational medical device, "CELLECTRA," which it uses to help its DNA medicines enter the body's cells for purported optimal effect. Inovio's lead product candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis ("RRP"), a life-long, rare disease of the respiratory tract caused by HPV infection

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) reported that its annual Total Revenue declined from $0.83 million in 2023 to $0.217 million in 2024, and that its Net Loss declined from $130.39 million in 2023 to $103.94 million in 2024.

On August 8, 2024, when, during post-market hours, Inovio Pharmaceuticals, Inc. reported its financial results and recent business highlights for the second quarter of 2024. Therein, Defendants revealed that Inovio expected to submit the INO-3107 BLA to the FDA in mid-2025-representing an approximate full-year delay from Defendants' initially projected mid-2024 submission timeline-because of "a manufacturing issue" with a component of the CELLECTRA device.

Then, on December 29, 2025, during pre-market hours, Inovio Pharmaceuticals, Inc. announced that the FDA had accepted the INO-3107 BLA on a standard rather than accelerated review timeline. Defendants advised that the FDA had indicated that the Company did not submit adequate information to justify eligibility for accelerated approval. Defendants further advised that Inovio does not plan to seek approval under the standard review timeline and would request a meeting with the FDA to discuss how it may still pursue accelerated approval.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) declined from $14.75 per share on April 01, 2024, to as low as $1.49 per share on January 06, 2026.

According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) common shares between October 10, 2023 and December 26, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 10, 2023 and December 26, 2025, the Defendants made false and/or misleading statements and/or failed to disclose that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Those who purchased shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.